TLR4 and serum lipopolysaccharide activity: Utilising in vitro and in vivo approaches, we found evidence that supports our hypothesis and suggests that TLR4 inhibition warrants further investigation as a therapeutic strategy for endotoxemia-associated muscle weakness.